Reduced amyloid burden after treatment with the antiamyloid donanemab (Kisunla) correlated strongly with slower cognitive and functional decline in adults with early symptomatic Alzheimer’s disease (AD) in a secondary analysis of the phase 3 TRAILBLAZER-ALZ 2 trial. The TRAILBLAZER-ALZ 2 study showed that donanemab effectively removed beta-amyloid plaques from the brain and demonstrated statistically significant slowing of cognitive and functional decline compared with placebo.
Link: Medscape Medical News (10/2025)
